Literature DB >> 9632809

Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.

Y Kanno1, T Kanno, C Sakakura, S C Bae, Y Ito.   

Abstract

The polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor (CBF) is a transcription factor composed of two subunits, alpha and beta. The gene encoding the beta subunit is disrupted by inv(16), resulting in the formation of a chimeric protein, beta-SMMHC, which is associated with acute myelogenous leukemia. To understand the effect of beta-SMMHC on PEBP2-mediated transactivation, we used a luciferase assay system in which contribution of both the alpha and beta subunits was absolutely required to activate transcription. Using this system, we found that the minimal region of the beta subunit required for transactivation resides between amino acid 1 and 135, which is known to dimerize with the alpha subunit. In contrast, beta-SMMHC, despite having this minimal region for dimerization and transactivation, failed to support transcription with the alpha subunit. Furthermore beta-SMMHC blocked the synergistic transcription achieved by PEBP2 and CCAAT/enhancer binding protein alpha. By using a construct in which the PEBP2 alpha subunit was fused to the glucocorticoid receptor ligand binding domain, we demonstrated that coexpressed beta-SMMHC tightly sequestered the alpha subunit in the cytoplasm and blocked dexamethasone-dependent nuclear translocation of the alpha subunit. Thus, the result suggess that beta-SMMHC inhibits PEBP2-mediated transcription via cytoplasmic sequestration of the alpha subunit. Lastly proliferation of ME-1 cells that harbor inv(16) was blocked by an antisense oligonucleotide complementary to the junction of the chimeric mRNA, suggesting that beta-SMMHC contributes to leukemogenesis by blocking the differentiation of myeloid cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632809      PMCID: PMC109009          DOI: 10.1128/MCB.18.7.4252

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  Drosophila homologs of the proto-oncogene product PEBP2/CBF beta regulate the DNA-binding properties of Runt.

Authors:  G Golling; L Li; M Pepling; M Stebbins; J P Gergen
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

2.  Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.

Authors:  A L Zaiman; A F Lewis; B E Crute; N A Speck; J Lenz
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

3.  The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation.

Authors:  S Meyers; N Lenny; S W Hiebert
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

4.  Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide.

Authors:  C Sakakura; Y Yamaguchi-Iwai; M Satake; S C Bae; A Takahashi; E Ogawa; A Hagiwara; T Takahashi; A Murakami; K Makino
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

5.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.

Authors:  T R Golub; G F Barker; S K Bohlander; S W Hiebert; D C Ward; P Bray-Ward; E Morgan; S C Raimondi; J D Rowley; D G Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

6.  The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.

Authors:  R Frank; J Zhang; H Uchida; S Meyers; S W Hiebert; S D Nimer
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

7.  Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2.

Authors:  A Takahashi; M Satake; Y Yamaguchi-Iwai; S C Bae; J Lu; M Maruyama; Y W Zhang; H Oka; N Arai; K Arai
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

8.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

9.  PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.

Authors:  U Testa; F Grignani; T Barberi; M Fagioli; R Masciulli; P F Ferrucci; D Seripa; A Camagna; M Alcalay; P G Pelicci
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

10.  Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.

Authors:  S A Shurtleff; S Meyers; S W Hiebert; S C Raimondi; D R Head; C L Willman; S Wolman; M L Slovak; A J Carroll; F Behm
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

View more
  20 in total

1.  Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein.

Authors:  I Kitabayashi; Y Aikawa; L A Nguyen; A Yokoyama; M Ohki
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

2.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

3.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

Review 4.  Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Authors:  Ya-Huei Kuo; Jing Qi; Guerry J Cook
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

5.  The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.

Authors:  B Lutterbach; Y Hou; K L Durst; S W Hiebert
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.

Authors:  A Mandoli; A A Singh; P W T C Jansen; A T J Wierenga; H Riahi; G Franci; K Prange; S Saeed; E Vellenga; M Vermeulen; H G Stunnenberg; J H A Martens
Journal:  Leukemia       Date:  2013-09-04       Impact factor: 11.528

Review 7.  Molecular biology in acute leukemia.

Authors:  Mireia Camós; Dolors Colomer
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

8.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

9.  PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis.

Authors:  Hee-Jun Wee; Dominic Chih-Cheng Voon; Suk-Chul Bae; Yoshiaki Ito
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

Review 10.  Core binding factor at the crossroads: determining the fate of the HSC.

Authors:  Kevin A Link; Fu-Sheng Chou; James C Mulloy
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.